Perspective: The Promise of Multi-Cellular Engineered Living Systems

PERSPECTIVE | OCTOBER 11 2018
Perspective: The promise of multi-cellular engineered living

systems 
Roger D. Kamm  ; Rashid Bashir; Natasha Arora; Roy D. Dar ; Martha U. Gillette; Linda G. Griffith;
Melissa L. Kemp; Kathy Kinlaw; Michael Levin; Adam C. Martin; Todd C. McDevitt; Robert M. Nerem;
Mark J. Powers; Taher A. Saif; James Sharpe; Shuichi Takayama; Shoji Takeuchi; Ron Weiss; Kaiming Ye;
Hannah G. Yevick; Muhammad H. Zaman
APL Bioeng. 2, 040901 (2018)

https://doi.org/10.1063/1.5038337

View Export
Online Citation
Articles You May Be Interested In
Revolutionizing biomedical research: The imperative need for heart–kidney-connected organoids

APL Bioeng. (February 2024)
Brain organoid-on-a-chip: A next-generation human brain avatar for recapitulating human brain physiology
and pathology
Biomicrofluidics (November 2022)
11 October 2024 11:03:32

Engineering in vitro human neural tissue analogs by 3D bioprinting and electrostimulation
APL Bioeng. (April 2021)
APL BIOENGINEERING 2, 040901 (2018)
Perspective: The promise of multi-cellular engineered living

systems
Roger D. Kamm,1,a) Rashid Bashir,2 Natasha Arora,1 Roy D. Dar,2
Martha U. Gillette,2 Linda G. Griffith,1 Melissa L. Kemp,3 Kathy Kinlaw,4
Michael Levin,5 Adam C. Martin,1 Todd C. McDevitt,6 Robert M. Nerem,3
Mark J. Powers,7 Taher A. Saif,2 James Sharpe,8 Shuichi Takayama,3
Shoji Takeuchi,9 Ron Weiss,1 Kaiming Ye,10 Hannah G. Yevick,1
and Muhammad H. Zaman11
1
Massachusetts Institute of Technology, Boston, Massachusetts 02139, USA
2
University of Illinois at Urbana-Champaign, Urbana, Illinois 61820, USA
3
Georgia Institute of Technology, Atlanta, Georgia 30332, USA
4
Emory University, Atlanta, Georgia 30322, USA
5
Tufts University, Boston, Massachusetts 02153, USA
6
Gladstone Institutes, San Francisco, California 94158, USA
7
Thermo Fisher Scientific, Frederick, Maryland 21704, USA
8
EMBL Barcelona, European Molecular Biology Laboratory, Barcelona 08003, Spain
9
The University of Tokyo, Tokyo 113-8654, Japan
10
Binghamton University, Binghamton, New York 13902, USA
11
Boston University, Boston, Massachusetts 02215, USA
(Received 2 May 2018; accepted 18 September 2018; published online 11 October 2018)
Recent technological breakthroughs in our ability to derive and differentiate

induced pluripotent stem cells, organoid biology, organ-on-chip assays, and 3-D
11 October 2024 11:03:32

bioprinting have all contributed to a heightened interest in the design, assembly,
and manufacture of living systems with a broad range of potential uses. This white
paper summarizes the state of the emerging field of “multi-cellular engineered liv-
ing systems,” which are composed of interacting cell populations. Recent accom-
plishments are described, focusing on current and potential applications, as well as
barriers to future advances, and the outlook for longer term benefits and potential
ethical issues that need to be considered. VC 2018 Author(s). All article content,
except where otherwise noted, is licensed under a Creative Commons Attribution

(CC BY) license (http://creativecommons.org/licenses/by/4.0/). https://doi.org/
10.1063/1.5038337
I. INTRODUCTION
Over the past several decades, bioengineers, biophysicists, and biologists have made steady
progress toward the creation of “multi-cellular engineered living systems” (M-CELS). These
systems are composed of living cells and tissues organized in a way that produces novel func-
tionalities by design. For present purposes, we consider the subset of M-CELS composed of
mammalian cells and used primarily for biomedical applications and exclude, for example,
other potentially important applications such as those in plant systems, energy harvesting, or
the microbiome. Defined in this way, it includes organ-on-chip or tissue chip systems being
developed for drug screening or disease models1,2 with the potential to expedite drug discovery
and provide important new insights into fundamental disease processes. It also encompasses
implantable “hyper-organs,” ones that, for example, sense a biological signal and synthesize
and secrete a biologic product in response. Also included are biological actuators or bio-robots
that have applications in various fields. These M-CELS might be assembled in vitro from
a)
Author to whom correspondence should be addressed: rdkamm@mit.edu
2473-2877/2018/2(4)/040901/21 2, 040901-1 C Author(s) 2018.

V
040901-2 Kamm et al. APL Bioeng. 2, 040901 (2018)
clusters of individually differentiated cells or co-differentiated within a single aggregate of plu-

ripotent cells. An important distinguishing feature is that these systems are designed to possess
a specific form and function by design to perform in ways that are not found in natural systems
today and ultimately that they can be produced in quantity and in a sufficiently robust manner,
thereby making them reliable and amenable to large-scale manufacture.
While we have a tremendous knowledge base to draw upon for the design and manufacture
of M-CELS, derived from the study and design of non-biological engineered systems, much is
not directly applicable to M-CELS. This is a consequence of at least two important features
that distinguish M-CELS from abiotic systems: first, our lack of a fundamental understanding
of their inherent complexity, and second, the central role played by emergence in M-CELS for-
mation. In this context, we define emergence as a self-directed, multicellular response occurring
as a result of collective interactions of individual cells between themselves and the extracellular
environment at microscale which manifests itself by phenomena at macroscopic, system-level
scale. Living systems, even at the level of a single cell, are remarkably complex. Cells employ
a vast array of signaling pathways to govern their phenotype and behavior, and when used as
the building blocks of multi-cellular systems, the complexity quickly becomes overwhelming.
Notably, models that are capable of predicting the phenotype of even a single simple cell from
its genotype are only now becoming available.3 When multiple cells and cell types interact,
new phenomena and properties emerge which can only be attributable to their collective behav-
ior and extend far beyond the capabilities of single cells. While these collective, emergent
behaviors are in principle predictable, they are enormously complex and arise from biological
reactions that are only partly understood. While there is little doubt that the transition from
single-celled organisms to more complex multicellular ones was absolutely essential for the
11 October 2024 11:03:32

richness of form and function we see in living systems today, our ability to understand and pre-
dict cell population behaviors remains nascent.
In order to make meaningful progress in developing the methods and tools needed to create
M-CELS, we must draw upon expertise from various disciplines. Certainly, various biological
sub-disciplines—synthetic biology, developmental biology, systems biology, and stem cell biol-
ogy—are essential as are engineering approaches reflected in biomaterials and tissue engineering.
However, we must also look into basic engineering design and manufacturing and a variety of
enabling technologies, in order to make meaningful progress. Relevant to this, the need for
“convergence” was recognized and articulated in the NRC Report, “Convergence: Facilitating
Transdisciplinary Integration of Life Sciences, Physical Sciences, Engineering and Beyond.”4
Convergence remains key to the development of M-CELS, across numerous sub-fields (Table I).
TABLE I. Disciplines needed for progress in M-CELS and brief description of their respective contributions.
Discipline or sub-discipline Contributions to M-CELS
Developmental biology Understanding emergence, morphogenesis, and repair of complex morphologies

in multi-cellular systems
Stem cell biology Providing the source cells for M-CELS
Synthetic biology Engineering robust genetic regulatory networks for co-differentiation and gene
editing to control cell behavior and regulate time-dependent protein synthesis
Mechanobiology Understanding how to control mechanical stimuli in a spatiotemporal manner in
order to direct cell and tissue behavior and regulate co-differentiation
Tissue engineering Creating the ability to design and fabricate simple multicellular constructs for
medical applications
Biomaterials Providing appropriate cell-matrix scaffolds and mechanical and chemical stimuli
for M-CELS growth and stability
Biofabrication and manufacturing Developing a new approach to manufacture M-CELS that accounts for emergence
and complexity not present in abiotic systems
Multi-scale computational modeling Creating predictive platforms for the design of M-CELS for specific functions
Ethics for M-CELS Facilitating an open dialog on the benefits and potential concerns in M-CELS,
generating a “code of ethics” to guide researchers
While steady progress in each of these disciplines fuels our ability to create M-CELS, several
major recent advances are particularly enabling and noteworthy. First, the ability to reprogram
adult, committed cells to generate induced pluripotent stem (iPS) cells5 has freed us from reliance
on embryonic stem cells to form new organs or other systems. We can now differentiate induced
human pluripotent stem cells (iPSCs) into a variety of cell types and begin to construct complex
systems with a consistent genotype. Second, recent success in the growth of organ-like structures—
organoids—from embryonic stem (ES) or iPS cells has shown that it is possible to co-differentiate
cells into multiple cell types that begin to show the form, and in some cases, the function, of a real
organ.6 Third, with the help from several new government programs worldwide, these technologies
have been brought to bear on the growing field of tissue- or organ-on-a-chip development.
As we develop the enabling technologies for M-CELS, at least two approaches for fabricat-
ing M-CELS can be envisioned (Fig. 1), here viewed in the context of a simple muscle-actuated
sphincter or pump that requires a vessel lumen for flow, muscle to contract or collapse the vessel
locally, and neural control, possibly by the use of optogenetically modified cells and activation
by light. Both approaches begin with a concept and detailed mapping of the various cell types
needed to produce the end-product. In one approach, differentiated pluripotent or primary cells
are seeded or plated in a specified spatial pattern in two or three-dimensional constructs to pro-
duce the elements of the system. These may include, for example, an endothelial monolayer, a
pancreatic islet, a muscle strip, or a cluster of neurons. These elements are then arranged within
a device or substrate in such a way that they interact with each other in a desired manner. We
liken this approach to current “top-down” engineering design and assembly of complex systems
11 October 2024 11:03:32
FIG. 1. (a) Pathways to building a M-CELS. (b) Key steps to achieve the two distinct pathways. The wavy line in (a) shows
that integration across the two pathways could also be possible.
from simpler components, all according to a master plan for the complete, assembled M-CELS.
In contrast, one could fabricate a M-CELS beginning with a disordered collection of pluripotent
cells that are subjected to a variety of guidance cues—chemical, mechanical, electrical, and
genetic—either globally or locally, which induce the cells causing them to co-differentiate into
multiple cell types and self-organize into a new multi-cellular system. We define this to be an
“emergent engineering” approach. Figure 1 shows these two pathways and the potential for inter-
actions or cross-over between them.
At this early stage in the development of M-CELS technologies, we recognize the need to
look ahead and consider the eventual scientific, commercial, and ethical impacts of our
approaches and actions. The purpose of this paper is to provide a review of recent accomplish-
ments, assess current state-of-the-art in M-CELS, and point to future needs and challenges. We
also seek to foster a wider conversation of these issues, initiated in a Workshop on Engineered
Living Systems, held in Chicago, IL, in August 2016 and continued in August 2018.
II. DEVELOPMENTAL PROCESSES AND REGENERATION

The intricacy of the tissue/organ self-assembly represents the essence of what engineers
strive to emulate as we design M-CELS. In organoid systems, we seek to replicate, control, and
even deviate from normal developmental processes, so it is key that we understand these at a
fundamental level. In addition to the initial emergence of form via the progression of genomic
and biophysical processes, development and regeneration offer numerous examples of self-
organization and dynamic pattern homeostasis even after initial anatomical organization is
achieved.7
11 October 2024 11:03:32

The correct stereotypical size and morphology of a developing organ result from the inter-
play between signals that regulate individual cell behavior and mechanical and biochemical
feedback that emerges from interactions among many cells.8–12 A well-studied example of how
the organ size is achieved via this interplay is the Drosophila imaginal wing disc, which over a
period of 5 days grows from 50 to 50 000 cells and then stops. This growth is guided by
both the spatially distributed expression of growth factors (e.g., Drosophila bone morphogenic
protein (BMP) and Wnt homologues)13 and their resulting gradients and by mechanical forces
which influence tissue growth.14,15 A model that has emerged from this system is that the organ
size reflects an intricate balance between biochemical signals and tissue mechanics.16,17
Many kinds of embryos, especially mammals, can be split in half or joined together, still
resulting in a perfectly normal animal,18,19 revealing regulative pattern control. After embryonic
development, tissues can undergo various degrees of regeneration, supported by stem cells and
their niches. One example is the mammalian intestine, where in humans, the small intestinal
epithelial lining is renewed every 5 days. Other animals, such as salamanders, can regenerate
whole limbs, spinal cords, jaws, eyes, hearts, and portions of their brain, after damage.20,21 An
important aspect of regeneration is that, similar to embryonic growth, regeneration stops when
a structure of the correct size and shape has formed.22 A better understanding of how the cor-
rect dimension feeds back to alter cell differentiation, migration, and proliferation in precisely
the right way to bring the pattern closer to the appropriate target morphology would allow for
an altered homeostatic size and tissue function.23 Taken together, exploiting innate pattern-
restoration mechanisms would allow M-CELS to adapt to external perturbations and recover
rapidly from damage. This could be applied, for example, to M-CELS that can respond to atro-
phy in a native tissue, growing and maintaining its complementary size.
In addition to set-points for the organ size, there is organismal-level homeostatic control.
Planarian flatworms shrink and grow in allometric proportion, remodeling their entire body
continuously to the available cell number due to eating or starvation.24 Tails transplanted onto
the flanks of salamanders slowly remodel into limbs—a structure more appropriate to their new
location.25 Additionally, tadpoles with experimentally rearranged Picasso-style faces still meta-
morphose into normal frogs, as individual organs migrate through non-endogenous paths as
needed to build the correct frog face.26 The ability of an engineered organism to maintain its
correct shape through similar mechanisms is another strategy to ensure robustness upon damage
either during or after initial assembly, representing an important design challenge for a syn-
thetic morphology.
A key issue for the future of M-CELS and regenerative medicine is to find the appropriate
paradigm with which to enable direct modification of the shape for engineering and biomedical
applications. Currently, the assembly of correctly shaped and patterned tissues is limited by our
ability to manage their construction at a micro-level (e.g., cell type, cell position, and scaffold
used)—a major barrier to progress in the repair of complex organs such as hands and eyes.
These constructs are difficult to assemble directly but are routinely regenerated in vivo by some
model species. Alternatively, the self-assembly of organoids leverages endogenous patterning
cascades but comes at the cost of losing control over the final shape and pattern of the M-
CELS. Ultimately, a solution lies between these extremes, as a kind of guided self-assembly
that provides judicious tweaks to an otherwise self-directed endogenous cascade of morphogen-
esis,27,28 as further discussed in Sec. III. Advances in the field will depend on finding the mini-
mal amount of input required for a system to progress towards a desired complex outcome.
Promising approaches include activating master regulators of developmental programs (e.g.,
“build an eye here”) and learning to modulate biochemical and mechanical signals that trigger
pattern formation above the cell level (e.g., organ size and spatial relationship between organs).
Ever finer-scale reductionist analyses of the mechanisms of signaling at the cellular and sub-
cellular levels, which are progressing at a very rapid pace, are complemented by theoretical and
experimental approaches that quantitatively investigate the top-down, computational aspects of
pattern regulation employed in tissue shape generation and maintenance.29–31
It is essential to understand and exploit the inherent processes that direct patterning of com-
plex structures.32 Cells and tissues need to make many decisions about what to build, where,
11 October 2024 11:03:32

and when, in the control of growth and form. In our example of a muscle-actuated pump of
Fig. 1, multiple cell types arranged in a specific spatial pattern are needed. The required struc-
ture bears similarities to the embryonic heart that develops in a remarkably robust manner in
vertebrates,33 so we know that such signals can, in principle, be created and potentially deci-
phered. The logic of such processes is beginning to be understood, as inferred from studies of
molecular regulatory networks,34 the encoding of positional information,35 and bioelectrical
encoding of target states.36 Together, the biochemical and biophysical layers are being investi-
gated with the tools of information theory, control theory, and computational cognitive science
to develop interventions that target the biological systems’ perception, memory, and decision-
making about large-scale (morphological) properties.28,37 Moving beyond regulating just a few
molecular pathways, we will be able to provide multiplexed inputs to tissues which alter the
perception space of cells, leading to activation of desired morphogenetic and repair responses.
It is becoming increasingly possible to leverage the ability of tissues to robustly implement spe-
cific modular patterning tasks via self-modeling and goal-directed remodeling activity.38–41
III. CONTROLLING EMERGENCE

One of the greatest challenges in creating M-CELS is to regulate the spatio-temporal differ-
entiation of cells within a developing construct such as an organoid. This control can be exerted
in a variety of ways (Fig. 2). It has long been known that transcription factors, growth factors,
morphogens, etc., play a key role in cell-cell or cell-matrix communication, and these exert
their influence through activation of a multitude of intracellular signaling pathways. As men-
tioned in Sec. II, morphogens and their spatial gradients control many aspects of early develop-
ment and determine much of the pattern formation that occurs as cells respond in diverse ways
to various, and often multiple, local morphogen concentrations. In the case of organoid systems,
morphogens are often used to push cell differentiation down to a specific path in order to pro-
duce a certain cell type of the desired tissue. In the muscle-actuated sphincter or pump, we
require endothelial cells for the vessel, skeletal muscle for the pumping action, and motor neu-
rons for controlled activation. However, achieving the needed level of control is clearly beyond
current capabilities, as it is a major challenge to manipulate concentration gradients with the
precision found in embryos. So, this method lacks the spatial specificity required to produce
FIG. 2. Methods for controlling emergence in M-CELS. Following the design specifications (left), a collection of proce-
dures can be applied in a spatiotemporal manner to induce differentiation and organization of the cells (middle) to produce
the desired form and function (right).
11 October 2024 11:03:32

tissues with multiple cell types by design, as needed in the generation of a complex M-CELS
such as the pump of Fig. 1.
In the same way that chemical factors act to control the biochemical signaling pathways,
cellular and extra-cellular mechanics can also exert control over the cell function during devel-
opment.42 Force transmission through matrix, cells, and their constituent molecules, in fact, can
be thought of as a parallel “mechanical signaling pathway,” one that communicates with the
biochemical pathway via several channels, including changes in molecular confirmation. Thus,
as a result of force transmission through the extracellular matrix (ECM), cell-cell junctions, the
cytoskeleton, or the membrane, proteins might alter their binding affinities or expose cryptic
binding sites, stretch-activated ion channels might open, and cell surface receptors might
become activated.43,44 However, just as in the case of biochemical control, mechanical control
remains a relatively blunt tool to use for co-differentiation of cells into a desired spatial pattern.
Methods are being developed, however, drawing upon existing technologies such as optical or
magnetic tweezers or AFM, which offer finer control. Just as cells secrete factors to control bio-
chemical signaling, cells can also exert mechanical force internally or externally, as a means of
regulating their interactions.
An important layer of the morphogenetic field that orchestrates cell behavior is electric. All
cells, and not just excitable nerve and muscle cells, communicate electrically using the same
ion channels, neurotransmitters, and electrical synapses (gap junctions) which evolution opti-
mized into brains. Parameters such as resting membrane potential (Vmem) control proliferation,
migration, cell shape, and differentiation45,46 and interact with chemical gradients, gene-
regulatory networks, and tensile forces. More importantly, recent studies revealed that the
dynamics of bioelectric networks process a kind of tissue memory that specifies high-level
properties such as size control, organ identity, and axial polarity of the entire body plan.47
Recent developments of pharmacological and optogenetic techniques for specific manipulation
of bioelectric circuits in non-neural, somatic tissues have shown the ability to trigger appendage
regeneration, reprogram gut into complete eyes, alter the number of legs and heads, reprogram
tumors into normal tissues, and overcome mutations in key patterning genes.48,49 Bioelectric
properties control gene expression and chromatin state via a number of known transduction
mechanisms; major opportunities for advances in this field focus on cracking the bioelectric
code—the mapping of large-scale voltage gradient patterns onto organ-level outcomes.50,51
Given the degree of plasticity revealed by bioelectric controls of growth and form, advances in
this field will be an invaluable aid in the top-down programming of the shape in bioengineering
applications.
Genetic engineering of cells allows us “from the inside” to modify and extend the biologi-
cal programs that underlie cellular behavior, through the design and implementation of synthetic
gene regulatory networks.52 With the advent of the Cas9/CRISPR system,53 it is now possible
to edit the genome and dynamically regulate specific genes. Synthetic biology has evolved from
demonstrating a simple gene circuit in prokaryotes54,55 to large multi-input circuits in prokar-
yotes56 and eukaryotes.57 These circuits usually comprise genetically encoded sensors that
detect levels of intracellular and extracellular biomarkers, a computational core that processes
sensory information and makes decisions about which specific actions to take, and actuators
that affect the cell state and the surrounding environment. Initial emphasis in synthetic biology
focused on the creation of gene circuits that operate orthogonally to the cell, attempting to min-
imize bidirectional interactions and dependencies between the circuit and the host. In contrast,
genetic circuits fashioned for M-CELS must at their core be conceptually and practically
embedded within the host and tissue, responding to dynamically changing cellular and extracel-
lular conditions and controlling the cellular milieu towards desired phenotypes.
Unlike many traditional approaches in engineering, M-CELS must develop the capability
to cope with or exploit the heterogeneity of cell types, states, environmental conditions, and
fluctuations in gene expression (or “noise”). Engineering noise of M-CELS will require address-
ing noise at multiple-scales throughout development. Predictive modeling and advanced tools to
modulate the noise of genetic and regulatory circuits within the cell will be needed.58–61
Addressing these issues within an ensemble includes accounting for the coupling of fluctuations
11 October 2024 11:03:32

in cell-to-cell signaling and the microenvironment. This presents an opportunity to develop
noise engineering approaches in both single-cell and multi-cellular systems. Engineering
stochasticity using synthetic systems58,59 or exogenous drug targeting60 of gene circuits and reg-
ulatory motifs and networks can bias cell-fates and provide a role for stochastic noise engineer-
ing of growth and pattern development.62,63 Integration of engineering noise and stochasticity
into the fundamental framework of bioengineering living systems can account for an iterative
design of fluctuations in signaling pathways at both single- and multi-cellular levels.
Other methods that hold promise for localized control in M-CELS are optogenetics,64 using
light-activated ion channels, and magnetogenetics,65 locally activating ion channels, applying
force, or precisely controlled heating. In these, either light or magnetic fields, often in combina-
tion with nanoparticles, are used to control local processes. For example, in the sphincter/pump
of Fig. 2, activating spatially separated cells to differentiate into the three indicated cell types
might be accomplished by localized stimulation. This might be accomplished by focusing light
of different wavelengths at cells engineered to synthesize specific transcription factors through
the use of optogenetics. The capability of such spatiotemporal activation, however, has yet to
be demonstrated, and remains an obstacle to progress.
Thus, cells possess a variety of regulatory mechanisms, and each of these provides a means
of regulating cell differentiation and function in the generation of M-CELS and, in particular,
to exert control over the morphogenesis of organoid systems. To do so requires more than
merely a collection of “tools” that can be used to manipulate the system; instead, it would need
a systematic approach to gaining a more fundamental understanding of the principles that deter-
mine form and function. Moreover, such an understanding would then facilitate generation of a
set of design principles, as described in Sec. VII. This represents one of the major challenges
of the field going forward.
IV. ORGANOIDS
Several recent scientific advances have helped seed the nascent field of M-CELS, but none
more so than those in organoid culture systems. Organoid, in this context, refers to an aggregate
of multiple organ-specific cell types structured similarly to the in vivo organ and sharing its key
functions. Research in organoids, built on work that started in the early 1900s,66 is now
accelerating as it incorporates recent advances in stem cell biology. Numerous publications

have identified culture conditions that support the differentiation of pluripotent stem cells
(PSCs) and the differentiation and/or self-renewal of adult stem cells in a manner that produces
organoids.67,68 PSCs have been differentiated into organoids representing a variety of organs or
complex systems including but not limited to the liver, brain, small intestine, stomach, pan-
creas, lung, kidney, and esophagus.69–80
While there are large gaps in our understanding of the mechanisms of organoid formation,
such as the rules that govern morphogenesis, regulate the size and shape, and lead to the emer-
gence of adult stem and progenitor populations, researchers are able to successfully maintain
organoids in culture for extended periods of time.67,77 The most common approach to develop-
ing an organoid culture system has been to follow nature’s template, translating findings from
developmental biology to direct differentiation in vitro. However, there are likely alternative
paths that could produce similar results because in vitro systems are freed from evolutionary
pressures and the dynamics of a complex organism. Discovering these “short circuits” to
achieve emergent organoid features will likely be a vibrant area of research moving forward. A
point of caution is whether or not the resulting organoid from such an approach will be suffi-
ciently similar in form and function to the organ and whether or not it will suffice for its engi-
neered purpose.81,82
Despite the advances made in the last six years in a variety of tissue types, many chal-
lenges remain to further development of organoid systems. Many of these challenges stem from
a lack of fundamental understanding associated with the biochemical, physical, and mechanical
drivers of differentiation within a multicellular environment which give rise to aggregates with
the form and function of organs. For example, how do asymmetrical structures emerge? What
11 October 2024 11:03:32

structural components are critical for the emergence of the desired function? And why is there
such variability in how PSCs respond to morphogenic cues? Some of the variability is due to
stochasticity or underlying biological noise (see also Sec. III). Engineering approaches may
ultimately leverage this stochasticity to drive differentiation or “canalization” in directions that
otherwise would be unfavorable under naturally occurring conditions. The same features that
give rise to cellular heterogeneity, however, also result in inconsistency with organoid differen-
tiations regardless of the tissue type, which is a barrier to wider scale adoption of organoid
systems in industrial screening settings.
Before organoids can readily be incorporated into M-CELS or used at an industrial scale,
there are practical implementation issues to address. First, at each stage of organoid formation,
the ability to scale in batches for suitable use in a high-throughput screen (e.g., >10 000 small
molecule compounds) is limited. Second, existing protocols do not address a fundamental issue
of how heterotypic tissues may have varied nutritional requirements and media needs; currently,
a given organoid will be supported by a common medium and culture conditions. Third, organo-
ids can be cultured long-term, but like other PSC derivatives, they tend to arrest developmentally
before reaching a mature, adult-like stage.83 Furthermore, the current repertoire of organoids
does not contain all organ-specific cell types or contain mature cell types from other systems,
like the circulatory or nervous systems. Finally, most of these organoid systems still rely on
undefined, highly variable components such as Matrigel and serum, which restricts our ability to
control and fine-tune the emergence of organoids. These factors contribute to the variable rates
of success in creating an organoid and our inability to alter the resulting structure, by design, to
produce new functionalities.
Many groups are working to address these issues both by furthering our understanding of
the principles governing organoid emergence and also developing new tools to aid in these
studies and provide new methods of manipulating the differentiation cultures. For example, the
development of on-chip culturing devices provides more sophistication in geometric arraying
for imaging and recovery for later biochemical analysis. Tunable hydrogels will enable detailed
analysis of the role of the matrix,84 and biosensors for metabolic studies will be valuable tools
to find common medium and culture conditions.85 Microfluidic devices can be designed to sup-
port analysis methods such as smFISH and immunofluorescence.86 Novel tools for multicellular
image digitization into network properties87 have allowed for extraction and quantification of
emergence, but more computational methods need to be developed in order to identify and pre-
dict desired features of organoid development, especially if large industrial-scale manufacturing
of these systems is needed for the next generation of drug development.
V. ORGAN-ON-CHIP MODELS
Building on the success of microfluidic technologies and iPS and stem cell engineering and
driven by the widely recognized need for transformative changes in the process of drug discov-
ery and development, a variety of new assays have been advanced which enable certain aspects
of the organ function to be replicated with in vitro models. While the “organ-on-chip” (OoC)
technologies are still at a relatively early stage in development, nascent versions of cardiac mus-
cle,88,89 liver,1,90 brain,91–93 lung,94 skin,95 placenta,96 and various other tissues have been
reported (Table II). Similar systems have been created for the purpose of modeling and gaining
new insights into fundamental disease processes such as cancer97 and Alzheimer’s disease.98
Given the increasing availability and reduced cost of generating iPS cells, the prospect of devel-
oping patient specific assays to screen for optimal personalized therapies is on the horizon.
Practical challenges include phenotypic instability, low throughput associated with system
complexity, material-drug incompatibilities of commonly used device materials such as PDMS,
and biomaterial inconsistencies and limitations. A fundamental question for OoC technology is,
will we be able to create microscale constructs that adequately recapitulate the macroscopic
organs? There is a danger, even if we construct OoC using human cells with sufficiently mature
phenotypes, that the resulting system will have the physiology more reminiscent of a small rodent
rather than the humans from whom the cells were originally derived. Two major scaling issues
11 October 2024 11:03:32

arise in OoC design and construction: (i) maintaining absolute values of physiological parameters
and (ii) maintaining relative sizes between different types of cells, tissues, and organs.
One example of changes in absolute physiological parameters due to scaling involves cellu-
lar level metabolic rates.104 As the size of an animal decreases, the basal cellular metabolic rate
increases. Importantly, this does not occur because of cell-intrinsic differences in the metabolic
rate. Instead, the basal metabolic rate of cells is dictated by the rate of nutrients and oxygen
delivery. Thus, in the typical, nutrient-, and oxygen-plentiful culture environments, human cells
TABLE II. Example organ-on-chip designs of different physiological functional units. A wide range of organ mimics have
been reported which recapitulate the basic functionality of that organ.
Tissue or organ system on-chip Description References
Lung alveolus Alveolus with endothelial and epithelial monolayers. Huh94

Time-varying vacuum in side chambers provides for
transient strain.
Liver Functionally active hepatocyte tissues maintained in a Domansky1
perfusable multi-well format.
Heart Cardiac muscle is seeded on a flexible cantilever so that the Lind88
magnitude of contractile force can be measured.
Microvascular Vascular networks formed by a vasculogenesis-like process Kim99
Placenta Multilayered system for co-culture of human trophoblast White87
cells and human fetal endothelial cells replicating in vivo
spatial organization.
Skin Skin represented by an epidermal layer is integrated with a Morris82
perfusable vascular channel for cosmetic testing.
Blood-brain barrier Blood-brain-barrier containing an endothelial layer, Booth100 and Campisi101
astrocytes, and pericytes including the measurement of
permeability.
Neurovascular An endothelial barrier with interacting astrocytes and Adriani93
neurons in separate gel regions.
Neuromuscular junction Neurosphere formed from optogenetic motor neurons Uzel and Morimoto 102,103
extending neurites to connect with skeletal muscle.
and even faithfully constructed minimal functional tissue units would metabolize at mouse-like
rates rather than human-like rates. While there are potential solutions such as limiting oxygen
availability,105 effective implementation in OoC systems is still a challenge.
Even if one were to achieve human-like physiological parameters for each organ module,
another challenge arises when connecting multiple OoCs together with a common medium that
might be circulated by our muscle-actuated pump example. If we shrink all linear dimensions
proportionally, the multiple OoC system will not reflect human proportions in terms of function.
For example, if a lung is isometrically miniaturized by a factor of 100, the surface area avail-
able for gas exchange falls nearly 10 000-fold. The same change in linear dimension for muscle
would reduce oxygen consumption rates by a factor of 106. Some potential solutions include
“functional scaling” of organs where miniaturization factors would be assigned to different
organs based on whether the organ function depends more on its surface area or its vol-
ume.104,106 While these and other potential solutions have been proposed,107–109 effective
implementation and validation in OoC systems remain a significant challenge.
While the long-term goal may be the construction of an OoC that reproduces all aspects of
human physiology, the near-term opportunity may be in fit-for-purpose OoCs that test for specific
aspects of efficacy or toxicity. Such efforts will require close collaboration with target end-users
to develop OoCs with “just enough complexity” to provide a valuable physiologic readout while
also allowing for a robust and high throughput assay. The systems will also have to be extensively
validated against existing gold-standard animal models using a large panel of reference chemicals.
A helpful resource with various examples of validating non-animal technologies is The European
Union Reference Laboratory for Alternative to Animal Testing (eurl-ecvam.jrc.ec.europa.eu).
Finally, the continuing difficulties in predicting adverse immune responses and the emergence of
11 October 2024 11:03:32

a range of successful immunotherapies suggest a need and opportunity for OoCs that replicate
tissue-level aspects of immunity.
VI. BIOLOGICAL ROBOTICS

An important application of M-CELS could be in the development of biological robotics
and actuation systems.110 Over the years, engineers have produced a variety of non-biological
robots and machines with an immense impact on our lives and industrial production. However,
they have fundamental limitations when compared to living systems, e.g., they cannot self-
emerge, self-assemble, or self-heal. On the other hand, in nature, meso- and macro-scale func-
tional organs and organisms (machines) emerge through complex interactions between individual
cells and the extra cellular matrix. Organs, in turn, interact with one another through precise
control algorithms that maintain homeostasis. However, the rules of the interaction between liv-
ing biological components at various hierarchies and spatio-temporal scales remain elusive. With
new methods of culturing and manipulating living cells, there is a growing interest in developing
cell-based biological robots, many with engineered scaffolds. It is envisioned that such robots
may have unprecedented capabilities, as they could reap the benefits of evolutionary pressures.
As an example, the development of biological actuators can form the building block of
more complex emergent systems. Such engineered biological actuators consist of muscle cells
(primary, cell lines or differentiated from stem cells or iPSCs), supporting cells such as fibro-
blasts, and an extracellular matrix (ECM) and may require a scaffold as a substrate. The cells
interact with the ECM and remodel it (compact and align fibers of the ECM), approach,
align111 and fuse with each other, undergo myogenesis, and emerge as muscle strips anchored
to the scaffold. Unlike cells in other organoids, muscle cells interact over long distances using
mechanical force. These complex interactions, both local and distant, involving diffusion and
mechanical forces, result in an emergent muscle system that possibly maximizes force and
motion and minimizes energy demand. Thus, the design of a muscle system involves solving an
inverse engineering problem—given a prescribed form and function of the system, choose the
appropriate scaffold and its biomaterial, ECM, and the muscle cell type and density.
Using the above principles, engineered muscle systems have been developed for in vivo
applications such as cardiac tissue repair112 and in vitro applications such as pumping fluids at
small scale113 and phenotypic assessment of neuromuscular disease.114 A variety of muscle sys-
tems have been explored to achieve multi-dimensional and complex motion and deformation
from muscle contractions on 2D and 3D substrates.115 These engineered systems serve as a test
bed for studying muscle force, their temporal dynamics, longevity, and overall performance in
contrast to their in vivo counterparts, with the ultimate goal of providing muscle repair, analysis
of muscle disease, and evaluation of drug efficacy. More interestingly, it is now possible to use
human iPSCs to form patient specific self-organized muscle strips to develop disease models
for prognosis, to interrogate disease mechanisms, and to study drug effects116 for individualized
medicine. Recognizing that muscles are often activated by neurons for both voluntary and
involuntary motions, recent work with M-CELS also involves muscles innervated by neurons,
forming functional neuromuscular junctions.102
The force and deformation attributes of engineered muscle systems have recently been
employed to generate locomotion of small structures. They include swimming in fluids mimick-
ing flagella dynamics at small scale (low Reynolds number),117 coordinated flapping dynamics
at larger scale (high Reynolds number),118–120 and walking using leg-like structures.115,121–124
These small robots move autonomously with cardiomyocytes as actuators, or they are stimu-
lated to move by light or an electric field when optogenetic or regular skeletal muscle cells are
used to actuate them. Through these elementary systems, we are learning to imitate different
capabilities of natural organisms, including locomotion and active transport, which can lead to
new applications.125 These include future in vivo applications in drug delivery and micro-
surgery. However, major challenges need to be overcome, including the issues with biocompati-
bility, imaging and control of trajectories, viability, and their removal after the desired function.
In the near term, they serve as test beds for studying emergent properties of biohybrid robots
11 October 2024 11:03:32

arising from clusters of heterotypic cells, ECM, and scaffolds. In the medium and long-term,
such top down engineered biological robotics could consist of many more cell types to achieve
specific functions and applications in the environment, energy, medicine, and others.
VII. DESIGN PRINCIPLES

Success of engineering systems rests on the formulation of effective design principles that
guide the creation of complex systems. Accordingly, achieving the M-CELS goals of creating
complex synthetic multicellular structures with defined behaviors will require the establishment
of experimentally verified rules and practices that guide the efficient and predictable formation
of these systems. The key to success will be the integration of traditional engineering concepts,
such as creating and characterizing reusable parts, establishing rules for the composition of
such parts, appropriate layers of abstraction, and modular system design, along with design
principles that take into account the unique properties and interactions of the biological sub-
strate. In other engineering disciplines, one can achieve desired behavior by exerting fine-grain
control over system components. In contrast, while precise spatiotemporal control over specific
elements of a living system is becoming feasible, regulating all aspects at all times is not realis-
tic. As such, a different approach must underlie our biological system design efforts.
However, while traditional engineering approaches may have limitations, if they are pursued
with regard to the biological substrate, it is important to note that M-CELS efforts should be
inspired by, but not limited to, natural designs. Design principles that have emerged from the evo-
lution of biological systems are instructive regarding what works and what does not work in a bio-
logical context. However, evolution is incremental and produces intermediate designs that are both
functional and competitive within their environmental context. In contrast, M-CELS and their
designs are not constrained in the same manner. Both top-down and emergent engineered systems
may favor configurations that are easier to understand, intentionally support and simplify future
enhancements and modifications, and arrive at solutions that leapfrog existing designs.
Several fundamental properties of living systems introduce challenges to engineering
design. Importantly, the high-level behavior of living systems emerges from the properties and
interactions between their constituent low-level components.126 To design M-CELS effectively,
we must consider the vast range of scales in which they operate (from the subcellular to the
organismal) and the need to integrate different control modalities. In biology, as in other areas,
the system function is tightly interwoven with the structure. The structure/function relationship
manifests itself at different scales of living systems, and it is also impacted by the numerous
ways in which cellular systems exert control over themselves and their surroundings. In the
efforts to engineer living systems, we have at our disposal a large set of proven methods for
manipulating biological behavior. It can be modulated “from the outside” via micro and macro-
scale methods described in Sec. III.
To fully realize the potential of M-CELS, these control methods can serve as composable
functions. These functions should have inputs and outputs and perform some transformation on
the living systems. The functions operate in space and time and at defined scales. While they
always perform operations physically, their impact can be both physical and regulatory/informa-
tion-processing. Functions have specific energy usage, operate at different modalities, and may
require coordination among multiple cells and time scales. While the concept of a function is
relatively straightforward, implementing a design framework that effectively integrates different
modes of control modalities as discussed in Sec. III remains a challenge. 3D multicellular simu-
lation tools such as Morpheus127 and others87,128 integrate gene regulation, cell signaling, and
biomechanics and may serve as a useful basis for M-CELS design tools. However, missing are
effective abstractions that support M-CELS 3D organ and multicellular machine design objec-
tives, akin to gene circuit design tools.129–132
VIII. ENABLING TECHNOLOGIES AND COMPUTATIONAL METHODS

New scientific directions inevitably require new technologies. In the context of M-CELS,
11 October 2024 11:03:32

we have already encountered technological limitations for sensing, modeling, and reengineering
of the form and function of cell-based systems. Technologies are needed for the formation and
characterization of organoids and cellular clusters, 4D imaging of these biological systems, 3D
dimensional patterning and fabrication, flexible means of providing bioelectric and metabolic
stimuli during guided self-assembly, and computational approaches capable of predicting the
behavior of cell populations of multiple cell types whose form and function emerge over time.
Enabling technologies can be categorized in terms of where they fit within the life cycle of
a M-CELS. First, the systems need to be assembled or arranged into a configuration that facili-
tates emergence and self-assembly. Technologies such as 3D printing, biomaterial scaffold
design, and advanced microfluidics have already demonstrated their benefits and potential but
need further development. Microfluidics has the capability of culturing cells in 3D with multi-
ple communicating cell types that can be arranged through 3D printing so as to facilitate the
essential interactions needed to generate the necessary cell-cell and cell-matrix interactions and
realization of autonomous operation of these systems in a wide range of environments and
ambient conditions.
Methods are also needed to interrogate the developing systems and to assess their final out-
come—the end product of the biomanufacturing process. Imaging will be key, but we are now
facing limitations in terms of our ability to visualize the structures deep inside a M-CELS,
especially in a label-free manner in live cells over time. Methods such as CLARITY133 and
3DISCO134 and their variations have already proven useful for imaging large multicellular con-
structs, but these, too, have limitations and provide little opportunity to assess the cell function-
ality of internal structures.
Another consideration is the need to assess system stability over time. Unlike abiotic
systems, M-CELS have the tendency to continue to change with time. Some aspects of
change—adaptability and self-repair—have benefits, but others such as loss of differentiation
and progressive cell death are clearly detrimental to function. It will therefore be necessary to
incorporate methods to continually assess the stability of the system so as to ensure its perfor-
mance. Functional measures such as the secretion rate of an essential chemical or force genera-
tion are examples.
In addition to experimental work, computational approaches will be required at every step
and closely coupled with experimental data, to analyze, predict, and probe the system’s
operation. Synthetic biology at the single-cell level has had many successes,56,57 but it has also
had to accept that progress has been slower than once hoped.135 One of the many challenges is
the non-intuitive behavior of molecular circuits: complex topologies, non-linear relationships,
and feedback loops often make the dynamics of a circuit impossible to predict without the aid
of computer simulations—these unexpected behaviors may be considered as examples of the
emergence, discussed above. Much of this work still revolves around trying to understand the
dynamics of simple circuits that are already constructed rather than trying to design de novo cir-
cuits, but this ambitious challenge of engineering new circuits is also gaining ground.34,130–132
Switching from single-celled circuits to multicellular systems brings a level of complexity
for computer modeling. Feedback loops now exist at more scales than the purely molecular.
Although the active dynamics of cells are known to be largely controlled by their molecular
states, it is now equally clear that macroscopic events directly feed back to control molecular
events. For example, tissue growth may push a group of morphogen-secreting cells away from
their target cells, thus changing their expression profiles as a direct consequence. If the behavior
of feedback loops in single-celled gene circuits is hard to predict, the complexity of these
multi-cellular and multi-scale feedbacks is dramatically more challenging. That is, the degree of
complex and subtle emergence is even higher than for molecular circuits alone. Understanding
and predicting them will not be possible without good computer models, so a clear expectation
for the future is that multi-scale numerical simulations must become a key goal for M-CELS.
A wide variety of modeling formalisms exist to tackle multi-cellular systems. At one end
of the spectrum are continuum approaches such as Finite Element Modeling (FEM), which
approximate a tissue as a continuous material, and they are optimal for questions involving
physical mechanics.136 At the other end of the spectrum, Cellular Potts Models (CPMs) employ
11 October 2024 11:03:32

many discrete variables on a lattice of points to represent each cell of the tissue.137 They can
therefore capture the irregular shapes of individual cells and have been used to simulate various
developmental processes,138 as well as tumor growth and vasculogenesis.139 However, for
general-purpose modeling of engineered tissues, their computational cost and limitations in rep-
resenting the mechanical integrity of large-scale structures (e.g., macroscopic bone or cartilage
elements) make them unlikely to become the primary formalism of choice for M-CELS. In
between these two extremes are a collection of techniques which together may be termed off-
lattice methods: agent-based models are often defined in terms of logic-based rules, or “state-
charts,” and have been particularly successful for cases where the primary scientific question is
about the control of differentiation through discrete cell states or fates.140 Vertex models in con-
trast have been used mostly to explore the physical mechanics of cellular interactions—how
different types of cell divisions affect the packing and cell shape.141 Since this formalism
explicitly represents the boundaries of cells, it is only really optimal for epithelial tissues hav-
ing a neat polygonal packing arrangement. For volumetric 3D tissues such as mesenchyme,
particle-based or cell-centroid models are preferable. They cope well with arbitrary 3D arrange-
ments of cells, without the computational overhead of maintaining mesh integrity. At the same
time, they are ideal for simulating the molecular aspect of the system—cell autonomous reac-
tions can be calculated on each particle, and diffusion can be well-approximated by exchange
of molecular concentrations between adjacent cells. Impressive results have recently been dem-
onstrated for early zebrafish development and gastrulation.142,143
Despite exciting improvements in these modeling approaches, we should be cautious about
predicting the use of computer modeling as a tool for “rational” design of multicellular M-
CELS. Thus far, the design principles found to be useful tend to exist at specific scales. For
example, at the lowest scale of small molecular circuits, we may use the design concepts of
Boolean logic or dynamical systems theory (attractors in phase portraits, etc.).34,56 At the inter-
mediate scale of multi-cellular pattern formation, we can employ the unifying concepts of posi-
tional information or self-organized patterning.144,145 While at the scale of macroscopic tissues,
interactions between active tissue growth and the material response properties of the tissue can
also lead to design principles based on physical mechanics (the control of stress distributions,
buckling, etc.).146 However, the interactions between design principles at different scales
have rarely been explored.147 Since a key feature of engineered tissues and organs is their
TABLE III. New technologies needed for the development and manufacture of M-CELS.
Technology Application to M-CELS
Imaging High resolution, high content imaging of large, multi-cellular structures, label-free methods,
and 4D imaging
Computational analysis Multi-scale modeling, agent-based methods, and data-driven modeling
Bioprinting Simultaneous printing of the matrix and multiple cell types with single cell resolution
Scaffold design Artificial and natural biomaterials with controllable chemistry and mechanical stiffness
Microfluidics Systems that facilitate spatiotemporal control of micro-environmental properties and co-
differentiation processes
Biofabrication Providing appropriate cell-matrix stimuli for organoid growth and stability and new
manufacturing methods that leverage intrinsic self-assembly
Optogenetics To facilitate the capability for spatiotemporal patterning of the function in growing M-CELS
Robotics Methods to handle high-volume production of organoids and other M-CELS for industrial
applications
multi-scale nature and we hope to control dynamic macroscopic processes through “molecular
programs,” it will probably take a significant phase of further basic research before computer
modeling aids us in “forward” rational design of these systems. Indeed, for the foreseeable
future, computer modeling research will probably focus on obtaining satisfactory models of
existing multicellular systems, and this will largely depend on “reverse-engineering” from large
quantitative datasets. Organoids may prove a particularly tractable system to work on in the
11 October 2024 11:03:32

short term, due to their both relative simplicity (compared to organs or embryos) and visual
accessibility for digitizing with time-lapse imaging.
IX. BIOMANUFACTURING
The biomanufacture of M-CELS poses significant challenges to existing bioprocesses.148
M-CELS present unique needs based on their inherent complexity and reliance on emergent
behavior. The overarching need—developing effective methods to reliably and robustly produce
M-CELS at a desirable scale—highlights a number of challenges and opportunities.
The development of M-CELS relies upon the integrated formation of cellular structures.
Such structures can be achieved through either self- or guided-assembly of multiple cell types
into functional units (see Sec. I). As we consider methods for manufacturing these systems, it
will be important to understand whether such complexity can be reduced or segmented in a
modular fashion to create M-CELS subunits, followed by assembly into desired M-CELS in a
controllable or bio-foundry manner. It is expected that efforts to better understand the phenom-
ena associated with emergence will help elucidate where such processes may be simplified or
deconstructed and where they cannot. The goal of such efforts is to enable the creation of a
“bio-assembly line” to achieve industrial scale production of desired M-CELS.
Biofabrication of subunits and their further assembly into M-CELS requires manufacturing
technologies across multiple disciplines (Table I) and technologies (Table III). Simple 2D and
3D cell culture methods can be augmented or replaced by newer technologies such as 3D bio-
printing,149–153 and automated bioreactor systems are key to enabling the generation of
compartmentalized M-CELS structures in an organized manner (Fig. 3). The continuing devel-
opment of effective 3D bioprinting technologies may enable the effective implementation of
this approach in M-CELS biomanufacture. Although the resolution that is currently achievable
with 3D bioprinting may not yet permit direct implementation on the length scales (10’s of
microns) required for M-CELS formation, they can help, at least, spatially position cells in a
manner that will facilitate further self-assembly and may prove to be effective tools for auto-
mating and standardizing key steps in M-CELS biomanufacturing.
Technologies that enable both scale up—relying on novel culture platforms with
increased capacity (e.g., bioreactors) and scale out—increasing the number of culture systems
FIG. 3. Manufacture of M-CELS. (a) Design and selection of cellular and substrate components. (b) Product manufacture
requiring a variety of manufacturing methods, many being unique to biological systems. (c) The manufactured product. (d)
11 October 2024 11:03:32

Post-processing considerations.
in use—will be of paramount importance to M-CELS biomanufacturing (Fig. 3).154 Improved

control of M-CELS biomanufacturing poses unique challenges based on the features that dif-
ferentiate M-CELS from traditional cell based systems—cellular complexity and emergent
behavior. Since cell-based processes are subject to inherent biological variability, the push
towards more defined and controllable components for use as cellular matrices and media is
imperative in minimizing “external” heterogeneity of M-CELS biomanufacturing. These vari-
abilities highlight the challenge for quality control (QC). Traditional cell-based products such
as primary cells or stem cells are developed with a mindset towards maximizing homogeneity
of the cell type(s) associated with these systems. As we begin to tackle the challenges of M-
CELS biomanufacturing, the heterogeneity of the cellular component is not just a possibility
but a necessity. Methods to understand and control this heterogeneity are therefore essential
in the successful biomanufacturing of M-CELS.
Furthermore, the biomanufacturing of M-CELS will necessitate the development of effec-
tive and appropriate assays for evaluating the M-CELS identity and function. These assays will
include the characterization of cell sources and biomaterials using many of the technologies
described in Sec. VIII. Ideally, these should be noninvasive or minimally-destructive to enable
live and real time monitoring of developing M-CELS. As our ability to discern the mechanistic
underpinnings of M-CELS development evolves, we also anticipate an increasing demand for
the use of molecular and analytical analysis in the selection of input materials. We already see
the consequences of the considerable variability in these fundamental components of a M-
CELS—variability in organoid formation from the same starting population155 and disparity in
directed differentiation of various pluripotent stem cells.156,157 These examples highlight differ-
ences that can occur under ostensibly identical extracellular environments. We anticipate that
technologies such as targeted sequencing, micro RNA analysis, epigenetic fingerprinting, and
proteomics will help elucidate and establish appropriate specifications for these cells, but much
work is needed before adequate procedures can be put in place.
Finally, the biomanufacturing of M-CELS demands the development of reliable tissue pres-
ervation technologies. While laboratory-scale M-CELS can be made and used on-demand,148
industry-scale production of these systems includes release and distribution of M-CELS through
supply-chains that are dependent upon reliable preservation. Cryo- or other preservation tech-
nologies of M-CELS pre-products or sub-assemblies will streamline and simplify the
manufacturing process. The ability to preserve completed M-CELS could enable building
“finished-goods” inventories and shipping to end-users.
X. ETHICAL CONSIDERATIONS
A fundamental question for researchers working in synthetic biology, emergent behavior,
and living systems is whether they are “creating life.” Some researchers in synthetic biology
believe microorganisms are “just” machines, and that the creation of new such machines
shouldn’t be considered differently.149 Others may argue that researchers need to be cognizant
of the degree to which projects might be perceived as creating life and what special obligations
might exist in this creative process. The language of “creating life” raises fundamental ques-
tions, including religious issues, for some observers who ask whether there should be natural
limits beyond which we should not be trespassing. While many of these issues have been raised
in the context of synthetic biology, they grow in importance when, for example, we become
able to produce a functioning brain organoid that can collect, process, and act based on infor-
mation gained from the environment. In addition, the concept of pain and sentience150,151 would
need to be addressed in the development of M-CELS that could be perceived as replication of
living entities. As many of the future M-CELS could by pass the natural developmental pro-
cess, the use of the 14 day rule150,152 employed to provide an ethical framework around embryo
research would have to be modified.153 We are also cognizant that some communities, in vari-
ous parts of the world, may be more sensitive to these concerns than others.
11 October 2024 11:03:32

Living systems’ research that replicates essential components of existing life forms may
also raise questions regarding whether there should be limits to scientific efforts that “re-create”
natural systems. Foundational to this discussion is the complexity of and current lack of full
understanding of the underlying biology and its emergence. Limited knowledge on biological
emergence makes it difficult to determine or project what the consequences might be of current
research. Indeed, the concept of emergence in complex systems raises the prospect of unfore-
seen outcomes in the M-CELS that are created, with potentially negative consequences. Efforts
to understand and incorporate system repair and healing pathways should also be assessed par-
allel to efforts to control or limit potential harmful outcomes. Designing “kill-switches” to halt
unforeseen harm provides one possible pathway but one that is potentially at odds with efforts
to support system self-repair.
A consequence-based analysis would include an assessment of the potential for harm and
dual use—in which the technology itself or resulting living systems may have unforeseen,
harmful applications with public health and security implications (e.g., bioterrorism). This anal-
ysis would also require discussion of possible safeguards that could be explored throughout the
research process.
Medical applications of M-CELS, particularly in connection with the creation of non-
natural organs (e.g., ones that might synthesize and secrete therapeutic factors for chronic
illness) or tissues with enhanced capabilities (e.g., a muscle “patch” containing cells that out-
perform natural muscle and thereby enhance athletic performance or an implant that enhances
mental acuity) raise new issues not previously considered. At what stage do we limit the use of
such performance enhancements? Would they only be accessible to a select few? Numerous
scenarios can readily be envisioned which raise important ethical questions for society.
The asserted goal of work in M-CELS is to support the greater good of society, identifying
constructive, efficient, new pathways for solving functional, real-world needs. As research in
M-CELS advances, acknowledging both “precautionary” and “proactionary” risk management
approaches/principles will be essential. The precautionary principle advises that when there is a
potential that harm may occur, researchers should use extreme caution, stopping research until
the potential for harm can be assessed.154 The proactionary principle, on the other hand, views
research as positive for society and assumes that research is beneficial unless there is evidence
to the contrary.155 An intermediate ethical position may provide a reasonable commitment to
both accountability and responsibility. Collaboration between researchers would provide a sys-
tem for checks and balances, with sharing of information between labs, while acknowledging
the tension such sharing would have with pathways for preserving research/publication rights.
M-CELS researchers, in close consultation with bioethicists, should develop a shared ethics
framework and consider creation of a shared governance structure.
It is unclear to what degree researchers and trainees who work on M-CELS are considering
or fostering discussion of these questions surrounding “creating” or “re-creating life” or control-
ling emergent behavior in their daily work. Those involved in research may benefit from an
intentional structure for identifying underlying, competing values and ethical principles in their
work and providing a forum for discussion, especially for trainees, about how scientific values
and personal values or beliefs coincide. The development of such a frame work and an ethics
code of conduct for M-CELS research is an imperative task for the research community to
develop. Being able to articulate the ethics underlying one’s work is so important in communi-
cating within the scientific community, with funders and policy makers and with the public at
large.
XI. CONCLUSIONS AND OUTLOOK

Following on recent advances in understanding single cell behavior156 and in develop-
ing simple, proof-of-concept biological machines,108,112 organoids,6 and organ-on-chip tech-
nologies,84 efforts are underway to develop the scientific and engineering principles that
will ultimately enable the development of M-CELSs. The approaches, however, are widely
divergent and often lack a sound basis due to the absence of a fundamental understanding
11 October 2024 11:03:32

of aspects unique to M-CELSs—complexity, the central role of emergence, and intrinsic
variability in the starting components—and fail to take advantage of their extraordinary
capabilities—self-assembly, growth, self-repair, adaptation, learning, etc.
In this opinion piece, we argue for the need to build on our current knowledge base for the
development and design of M-CELS, rethinking much of what we have learned from abiotic
engineered systems and to extend the concepts of synthetic biology to multi-cellular systems. A
major effort is required to characterize, model, and image the dynamical behavior of M-CELS
and consequently establish the design principles needed for their robust manufacture. Here, we
have presented some of the challenges that lie ahead in several of the key scientific and engi-
neering disciplines, as well as the potentially transformative benefits that could be derived from
this work. Much research is yet needed to understand cell population behavior to a level com-
mensurate with the need to establish sound principles for the development and design of future
M-CELS and to also develop an ethical framework for such research. Despite the challenges,
however, the potential benefits are enormous. While the scientific barriers are considerable, no
less are the social barriers that need to be addressed as we enter into this new era of engineered
living systems.
ACKNOWLEDGMENTS
We are grateful for support for the Workshop in Engineered Living Systems provided by the
NSF, UIUC, and MIT. This framework for research in this field at MIT, UIUC, and Georgia Tech
was funded by a National Science Foundation (NSF) Science and Technology Center on Emergent
Behavior of Integrated Cellular Systems (EBICS) (Grant No. CBET0939511), with additional
support from the NIH/NCI (U01 CA202177). We also wish to thank Janet Sinn-Hanlon,
DesignGroup@VetMed, University of Illinois, for creating the illustrations and Dr. Umer Hassan at
UIUC for reviewing this manuscript. M.L. gratefully acknowledges the support via the Allen
Discovery Center award from The Paul G. Allen Frontiers Group (12171) and the Templeton World
Charity Foundation (TWCF0089/AB55).
1
K. Domansky et al., “Perfused multiwell plate for 3D liver tissue engineering,” Lab Chip 10, 51–58 (2010).
2
S. N. Bhatia and D. E. Ingber, “Microfluidic organs-on-chips,” Nat. Biotechnol. 32, 760–772 (2014).
3
D. N. Macklin, N. A. Ruggero, and M. W. Covert, “The future of whole-cell modeling,” Curr. Opin. Biotechnol. 28,
111–115 (2014).
4
J. M. DeSimone, NRC Report, “Convergence: Facilitating Transdisciplinary Integration of Life Sciences, Physical
Sciences, Engineering and Beyond” (The National Academy of Sciences, Washington, D.C., 2014), p. 152.
5
Y. Avior, I. Sagi, and N. Benvenisty, “Pluripotent stem cells in disease modelling and drug discovery,” Nat. Rev. Mol.
Cell Biol. 17, 170–182 (2016).
6
A. Fatehullah, S. H. Tan, and N. Barker, “Organoids as an in vitro model of human development and disease,” Nat. Cell
Biol. 18, 246–254 (2016).
7
P. L. Townes and J. Holtfreter, “Directed movements and selective adhesion of embryonic amphibian cells,” J. Exp.
Zool. 128, 53–120 (1955).
8
A. Navis and M. Bagnat, “Developing pressures: Fluid forces driving morphogenesis,” Curr. Opin. Genet. Dev. 32,
24–30 (2015).
9
R. Peyronnet, D. Tran, T. Girault, and J. M. Frachisse, “Mechanosensitive channels: Feeling tension in a world under
pressure,” Front. Plant Sci. 5, 558 (2014).
10
C. J. Miller and L. A. Davidson, “The interplay between cell signalling and mechanics in developmental processes,”
Nat. Rev. Genet. 14, 733–744 (2013).
11
L. A. Davidson, “Epithelial machines that shape the embryo,” Trends Cell Biol. 22, 82–87 (2012).
12
T. Mammoto and D. E. Ingber, “Mechanical control of tissue and organ development,” Development 137, 1407–1420
(2010).
13
S. Restrepo, J. J. Zartman, and K. Basler, “Coordination of patterning and growth by the morphogen DPP,” Curr. Biol.
24, R245–R255 (2014).
14
C. Rauskolb, S. Sun, G. Sun, Y. Pan, and K. D. Irvine, “Cytoskeletal tension inhibits Hippo signaling through an Ajuba-
Warts complex,” Cell 158, 143–156 (2014).
15
T. Schluck, U. Nienhaus, T. Aegerter-Wilmsen, and C. M. Aegerter, “Mechanical control of organ size in the develop-
ment of the Drosophila wing disc,” PLoS One 8, e76171 (2013).
16
T. Aegerter-Wilmsen et al., “Integrating force-sensing and signaling pathways in a model for the regulation of wing ima-
ginal disc size,” Development 139, 3221–3231 (2012).
17
B. I. Shraiman, “Mechanical feedback as a possible regulator of tissue growth,” Proc. Natl. Acad. Sci. U. S. A. 102,
3318–3323 (2005).
18
C. A. Carter and J. P. Wourms, “Cell behavior during early development in the South American annual fishes of the
11 October 2024 11:03:32

genus Cynolebias,” J. Morphol. 210, 247–266 (1991).
19
A. K. Tarkowski, “Mouse chimaeras developed from fused eggs,” Nature 190, 857–860 (1961).
20
C. McCusker and D. M. Gardiner, “The axolotl model for regeneration and aging research: A mini-review,”
Gerontology 57, 565–571 (2011).
21
K. D. Birnbaum and A. S. Alvarado, “Slicing across kingdoms: Regeneration in plants and animals,” Cell 132, 697–710
(2008).
22
C. Herrera-Rincon, J. A. Guay, and M. Levin, in Regenerative Engineering and Developmental Biology: Principles and
Applications, edited by D. M. Gardiner (Taylor and Francis, Boca Raton, FL, 2017).
23
G. Pezzulo and M. Levin, “Re-membering the body: Applications of computational neuroscience to the top-down con-
trol of regeneration of limbs and other complex organs,” Integr. Biol. 7, 1487–1517 (2015).
24
L. Gentile, F. Cebria, and K. Bartscherer, “The planarian flatworm: An in vivo model for stem cell biology and nervous
system regeneration,” Dis. Model Mech. 4, 12–19 (2011).
25
N. Farinella-Ferruzza, “The transformation of a tail into a limb after xenoplastic transformation,” Experientia 12,
304–305 (1956).
26
L. N. Vandenberg, D. S. Adams, and M. Levin, “Normalized shape and location of perturbed craniofacial structures in
the Xenopus tadpole reveal an innate ability to achieve correct morphology,” Dev. Dyn. 241, 863–878 (2012).
27
R. Doursat, H. Sayama, and O. Michel, “Morphogenetic engineering: Reconciling self-organization and architecture,” in
Understanding Complex Systems (Springer, Berlin, Heidelberg, 2012), p. 1–24.
28
G. Pezzulo and M. Levin, “Top-down models in biology: Explanation and control of complex living systems above the
molecular level,” J. R. Soc. Interface 2016, 13.
29
J. J. Velazquez, E. Su, P. Cahan, and M. R. Ebrahimkhani, “Programming morphogenesis through systems and synthetic
biology,” Trends Biotechnol. 36, 415–429 (2017).
30
J. Briscoe and A. Kicheva, “The physics of development 100 years after D’Arcy Thompson’s ‘On Growth and Form’,”
Mech. Dev. 145, 26–31 (2017).
31
A. Abzhanov, “The old and new faces of morphology: The legacy of D’Arcy Thompson’s ‘theory of transformations’
and ‘laws of growth’,” Development 144, 4284–4297 (2017).
32
K. Friston, M. Levin, B. Sengupta, and G. Pezzulo, “Knowing one’s place: A free-energy approach to pattern regu-
lation,” J. R. Soc. Interface 12 (2015).
33
A. S. Forouhar et al., “The embryonic vertebrate heart tube is a dynamic suction pump,” Science 312, 751–753 (2006).
34
Y. Schaerli et al., “A unified design space of synthetic stripe-forming networks,” Nat. Commun. 5, 4905 (2014).
35
M. Tewary et al., “A stepwise model of reaction-diffusion and positional information governs self-organized human
peri-gastrulation-like patterning,” Development 144, 4298–4312 (2017).
36
F. Durant et al., “Long-term, stochastic editing of regenerative anatomy via targeting endogenous bioelectric gradients,”
Biophys. J. 112, 2231–2243 (2017).
37
M. Levin, G. Pezzulo, and J. M. Finkelstein, “Endogenous bioelectric signaling networks: Exploiting voltage gradients
for control of growth and form,” Annu. Rev. Biomed. Eng. 19, 353–387 (2017).
38
L. J. Bugaj, G. P. O’Donoghue, and W. A. Lim, “Interrogating cellular perception and decision making with optogenetic
tools,” J. Cell Biol. 216, 25–28 (2017).
39
A. Mitchell and W. Lim, “Cellular perception and misperception: Internal models for decision-making shaped by evolu-
tionary experience,” Bioessays 38, 845–849 (2016).
40
K. Friston, “Life as we know it,” J. R. Soc. Interface 10, 20130475 (2013).
41
K. Friston, “Active inference and free energy,” Behav. Brain Sci. 36, 212–213 (2013).
42
D. A. Thompson, On Growth and Form, 1st ed. (Cambridge University Press, 1917).
43
T. D. Ross et al., “Integrins in mechanotransduction,” Curr. Opin. Cell Biol. 25, 613–618 (2013).
44
G. Bao et al., “Molecular biomechanics: The molecular basis of how forces regulate cellular function,” Mol. Cell
Biomech. 3, 91–105 (2010).
45
D. J. Blackiston, K. A. McLaughlin, and M. Levin, “Bioelectric controls of cell proliferation: Ion channels, membrane
voltage and the cell cycle,” Cell Cycle 8, 3527–3536 (2009).
46
S. Sundelacruz, M. Levin, and D. L. Kaplan, “Role of membrane potential in the regulation of cell proliferation and dif-
ferentiation,” Stem Cell Rev. 5, 231–246 (2009).
47
E. Bates, “Ion channels in development and cancer,” Annu. Rev. Cell Dev. Biol. 31, 231–247 (2015).
48
M. Levin, “Reprogramming cells and tissue patterning via bioelectrical pathways: Molecular mechanisms and biomedi-
cal opportunities,” Wiley Interdiscip. Rev. Syst. Biol. Med. 5, 657–676 (2013).
49
A. Tseng and M. Levin, “Cracking the bioelectric code: Probing endogenous ionic controls of pattern formation,”
Commun. Integr. Biol. 6, 1–8 (2013).
50
J. Mustard and M. Levin, “Bioelectrical mechanisms for programming growth and form: Taming physiological networks
for soft body robotics,” Soft Rob. 1, 169–191 (2014).
51
K. G. Sullivan, M. Emmons-Bell, and M. Levin, “Physiological inputs regulate species-specific anatomy during embryo-
genesis and regeneration,” Commun. Integr. Biol. 9, e1192733 (2016).
52
L. Prochazka, Y. Benenson, and P. W. Zandstra, “Synthetic gene circuits and cellular decision-making in human pluripo-
tent stem cells,” Curr. Opin. Syst. Biol. 5, 93–103 (2017).
53
J. A. Doudna and E. Charpentier, “Genome editing. The new frontier of genome engineering with CRISPR-Cas9,”
Science 346, 1258096 (2014).
54
T. S. Gardner, C. R. Cantor, and J. J. Collins, “Construction of a genetic toggle switch in Escherichia coli,” Nature 403,
339–342 (2000).
55
M. B. Elowitz and S. Leibler, “A synthetic oscillatory network of transcriptional regulators,” Nature 403, 335–338 (2000).
56
T. S. Moon, C. Lou, A. Tamsir, B. C. Stanton, and C. A. Voigt, “Genetic programs constructed from layered logic gates
in single cells,” Nature 491, 249–253 (2012).
57
Z. Xie, L. Wroblewska, L. Prochazka, R. Weiss, and Y. Benenson, “Multi-input RNAi-based logic circuit for identifica-
tion of specific cancer cells,” Science 333, 1307–1311 (2011).
58
K. F. Murphy, R. M. Adams, X. Wang, G. Balazsi, and J. J. Collins, “Tuning and controlling gene expression noise in
11 October 2024 11:03:32

synthetic gene networks,” Nucl. Acids Res. 38, 2712–2726 (2010).
59
T. Lu, M. Ferry, R. Weiss, and J. Hasty, “A molecular noise generator,” Phys. Biol. 5, 036006 (2008).
60
R. D. Dar, N. N. Hosmane, M. R. Arkin, R. F. Siliciano, and L. S. Weinberger, “Screening for noise in gene expression
identifies drug synergies,” Science 344, 1392–1396 (2014).
61
J. M. Schmiedel et al., “Gene expression. MicroRNA control of protein expression noise,” Science 348, 128–132
(2015).
62
H. M. Meyer and A. H. Roeder, “Stochasticity in plant cellular growth and patterning,” Front. Plant Sci. 5, 420 (2014).
63
P. Prusinkiewicz, Y. Erasmus, B. Lane, L. D. Harder, and E. Coen, “Evolution and development of inflorescence
architectures,” Science 316, 1452–1456 (2007).
64
E. S. Boyden, “Optogenetics and the future of neuroscience,” Nat. Neurosci. 18, 1200–1201 (2015).
65
S. Nimpf and D. A. Keays, “Is magnetogenetics the new optogenetics?,” EMBO J. 36, 1643–1646 (2017).
66
H. V. Wilson, “On some phenomena of coalescence and regeneration in sponges,” J. Exp. Zool. 5, 245–258 (1907).
67
M. A. Lancaster et al., “Cerebral organoids model human brain development and microcephaly,” Nature 501, 373–379 (2013).
68
C. Willyard, “The boom in mini stomachs, brains, breasts, kidneys and more,” Nature 523, 520–522 (2015).
69
L. Broutier et al., “Culture and establishment of self-renewing human and mouse adult liver and pancreas 3D organoids
and their genetic manipulation,” Nat. Protoc. 11, 1724–1743 (2016).
70
J. Choi, E. Iich, and J. H. Lee, “Organogenesis of adult lung in a dish: Differentiation, disease and therapy,” Dev. Biol.
420, 278–286 (2016).
71
B. R. Dye et al., “In vitro generation of human pluripotent stem cell derived lung organoids,” Elife 2015, 4.
72
P. Guye et al., “Genetically engineering self-organization of human pluripotent stem cells into a liver bud-like tissue
using Gata6,” Nat. Commun. 7, 10243 (2016).
73
H. Hisha et al., “Establishment of a novel lingual organoid culture system: Generation of organoids having mature kera-
tinized epithelium from adult epithelial stem cells,” Sci. Rep. 3, 3224 (2013).
74
M. Hohwieler et al., “Human pluripotent stem cell-derived acinar/ductal organoids generate human pancreas upon ortho-
topic transplantation and allow disease modelling,” Gut 3, 473–486 (2016).
75
M. Huch et al., “Unlimited in vitro expansion of adult bi-potent pancreas progenitors through the Lgr5/R-spondin axis,”
EMBO J. 32, 2708–2721 (2013).
76
R. Morizane et al., “Nephron organoids derived from human pluripotent stem cells model kidney development and
injury,” Nat. Biotechnol. 33, 1193–1200 (2015).
77
J. R. Spence et al., “Directed differentiation of human pluripotent stem cells into intestinal tissue in vitro,” Nature 470,
105–109 (2011).
78
R. R. Zhang et al., “Efficient hepatic differentiation of human induced pluripotent stem cells in a three-dimensional
microscale culture,” Methods Mol. Biol. 1210, 131–141 (2014).
79
K. W. McCracken et al., “Modelling human development and disease in pluripotent stem-cell-derived gastric organo-
ids,” Nature 516, 400–404 (2014).
80
M. Takasato et al., “Directing human embryonic stem cell differentiation towards a renal lineage generates a self-
organizing kidney,” Nat. Cell Biol. 16, 118–126 (2014).
81
S. A. Morris et al., “Dissecting engineered cell types and enhancing cell fate conversion via CellNet,” Cell 158,
889–902 (2014).
82
S. A. Morris and G. Q. Daley, “A blueprint for engineering cell fate: Current technologies to reprogram cell identity,”
Cell Res. 23, 33–48 (2013).
83
D. E. Cohen and D. Melton, “Turning straw into gold: Directing cell fate for regenerative medicine,” Nat. Rev. Genet.
12, 243–252 (2011).
84
S. Allazetta, L. Kolb, S. Zerbib, J. Bardy, and M. P. Lutolf, “Cell-instructive microgels with tailor-made physicochemi-
cal properties,” Small 11, 5647–5656 (2015).
85
G. Chennell et al., “Imaging of metabolic status in 3D cultures with an improved AMPK FRET biosensor for FLIM,”
Sensors (Basel) 2016, 16.
86
E. L. Jackson and H. Lu, “Three-dimensional models for studying development and disease: Moving on from organisms
to organs-on-a-chip and organoids,” Integr. Biol. 8, 672–683 (2016).
87
D. E. White et al., “Quantitative multivariate analysis of dynamic multicellular morphogenic trajectories,” Integr. Biol.
(Camb) 7, 825–833 (2015).
88
J. U. Lind et al., “Instrumented cardiac microphysiological devices via multimaterial three-dimensional printing,” Nat.
Mater. 16, 303–308 (2017).
89
T. Boudou et al., “A microfabricated platform to measure and manipulate the mechanics of engineered cardiac micro-
tissues,” Tissue Eng., Part A 18, 910–919 (2012).
90
J. W. Allen and S. N. Bhatia, “Formation of steady-state oxygen gradients in vitro: Application to liver zonation,”
Biotechnol. Bioeng. 82, 253–262 (2003).
91
L. M. Griep et al., “BBB on chip: Microfluidic platform to mechanically and biochemically modulate blood-brain barrier
function,” Biomed. Microdev. 15, 145–150 (2013).
92
A. Herland et al., “Distinct contributions of astrocytes and pericytes to neuroinflammation identified in a 3D human
blood-brain barrier on a chip,” PLoS One 11, e0150360 (2016).
93
G. Adriani, D. Ma, A. Pavesi, R. D. Kamm, and E. L. Goh, “A 3D neurovascular microfluidic model consisting of neu-
rons, astrocytes and cerebral endothelial cells as a blood-brain barrier,” Lab Chip 17, 448–459 (2017).
94
D. Huh et al., “Reconstituting organ-level lung functions on a chip,” Science 328, 1662–1668 (2010).
95
N. Mori, Y. Morimoto, and S. Takeuchi, “Skin integrated with perfusable vascular channels on a chip,” Biomaterials
116, 48–56 (2017).
96
S. Miura, K. Sato, M. Kato-Negishi, T. Teshima, and S. Takeuchi, “Fluid shear triggers microvilli formation via mecha-
nosensitive activation of TRPV6,” Nat. Commun. 6, 8871 (2015).
97
M. B. Chen, J. M. Lamar, R. Li, R. O. Hynes, and R. D. Kamm, “Elucidation of the roles of tumor integrin beta1 in the
extravasation stage of the metastasis cascade,” Cancer Res. 76, 2513–2524 (2016).
98
Y. J. Choi et al., “Neurotoxic amyloid beta oligomeric assemblies recreated in microfluidic platform with interstitial
11 October 2024 11:03:32

level of slow flow,” Sci. Rep. 3, 1921 (2013).
99
S. Kim, H. Lee, M. Chung, and N. L. Jeon, “Engineering of functional, perfusable 3D microvascular networks on a
chip,” Lab Chip 13, 1489–1500 (2013).
100
R. Booth and H. Kim, “Characterization of a microfluidic in vitro model of the blood-brain barrier (muBBB),” Lab Chip
12, 1784–1792 (2012).
101
M. Campisi et al., “3D self-organized microvascular model of the human blood-brain barrier with endothelial cells, peri-
cytes and astrocytes,” Biomaterials 180, 117–129 (2018).
102
S. G. Uzel et al., “Microfluidic device for the formation of optically excitable, three-dimensional, compartmentalized
motor units,” Sci. Adv. 2, e1501429 (2016).
103
Y. Morimoto, M. Kato-Negishi, H. Onoe, and S. Takeuchi, “Three-dimensional neuron-muscle constructs with neuro-
muscular junctions,” Biomaterials 34, 9413–9419 (2013).
104
C. Moraes et al., “On being the right size: Scaling effects in designing a human-on-a-chip,” Integr. Biol. (Camb) 5,
1149–1161 (2013).
105
J. M. M. Labuz, C. Mertz, D. R. Leung, and B. M. Takayama, “S. Building an experimental model of the human body
with non-physiological parameters,” Technology 1, 42–59 (2017).
106
J. P. Wikswo et al., “Scaling and systems biology for integrating multiple organs-on-a-chip,” Lab Chip 13, 3496–3511
(2013).
107
H. E. Abaci and M. L. Shuler, “Human-on-a-chip design strategies and principles for physiologically based pharmacoki-
netics/pharmacodynamics modeling,” Integr. Biol. (Camb) 7, 383–391 (2015).
108
A. Ahluwalia, “Allometric scaling in-vitro,” Sci. Rep. 7, 42113 (2017).
109
C. L. Stokes, M. Cirit, and D. A. Lauffenburger, “Physiome-on-a-chip: The challenge of “scaling” in design, operation,
and translation of microphysiological systems,” CPT Pharmacometrics Syst. Pharmacol. 4, 559–562 (2015).
110
L. Ricotti et al., “Biohybrid actuators for robotics: A review of devices actuated by living cells,” Sci. Rob. 2, eaaq0495
(2017).
111
S. S. Anand and T. A. Saif, “Emergent dynamics of cardiomyocyte clusters on deformable polymeric substrates,”
Extreme Mech. Lett. 8 (2015).
112
W. H. Zimmermann, I. Melnychenko, and T. Eschenhagen, “Engineered heart tissue for regeneration of diseased hearts,”
Biomaterials 25, 1639–1647 (2004).
113
Y. Tanaka et al., “A micro-spherical heart pump powered by cultured cardiomyocytes,” Lab Chip 7, 207–212
(2007).
114
J. A. Steinbeck et al., “Functional connectivity under optogenetic control allows modeling of human neuromuscular dis-
ease,” Cell Stem Cell 18, 134–143 (2016).
115
A. W. Feinberg et al., “Muscular thin films for building actuators and powering devices,” Science 317, 1366–1370
(2007).
116
E. Tzatzalos, O. J. Abilez, P. Shukla, and J. C. Wu, “Engineered heart tissues and induced pluripotent stem cells: Macro-
and microstructures for disease modeling, drug screening, and translational studies,” Adv. Drug Delivery Rev. 96,
234–244 (2016).
117
B. J. Williams, S. V. Anand, J. Rajagopalan, and M. T. Saif, “A self-propelled biohybrid swimmer at low Reynolds
number,” Nat. Commun. 5, 3081 (2014).
118
J. C. Nawroth et al., “A tissue-engineered jellyfish with biomimetic propulsion,” Nat. Biotechnol. 30, 792–797 (2012).
119
S. J. Park et al., “Phototactic guidance of a tissue-engineered soft-robotic ray,” Science 353, 158–162 (2016).
120
R. Raman et al., “Optogenetic skeletal muscle-powered adaptive biological machines,” Proc. Natl. Acad. Sci. U. S. A.
113, 3497–3502 (2016).
121
J. Xi, J. J. Schmidt, and C. D. Montemagno, “Self-assembled microdevices driven by muscle,” Nat. Mater. 4, 180–184
(2005).
122
R. Raman, C. Cvetkovic, and R. Bashir, “A modular approach to the design, fabrication, and characterization of muscle-
powered biological machines,” Nat. Protoc. 12, 519–533 (2017).
123
V. Chan et al., “Development of miniaturized walking biological machines,” Sci. Rep. 2, 857 (2012).
124
C. Cvetkovic et al., “Three-dimensionally printed biological machines powered by skeletal muscle,” Proc. Natl. Acad.
Sci. U. S. A. 111, 10125–10130 (2014).
125
R. Raman and R. Bashir, “Biomimicry, biofabrication, and biohybrid systems: The emergence and evolution of biologi-
cal design,” Adv. Healthcare Mater. 2017, 6.
126
J. Davies, Mechanisms of Morphogenesis, 2nd ed. (Academic Press, Cambridge, MA, 2013).
127
J. Starruss, W. de Back, L. Brusch, and A. Deutsch, “Morpheus: A user-friendly modeling environment for multiscale
and multicellular systems biology,” Bioinformatics 30, 1331–1332 (2014).
128
M. H. Swat et al., “Multi-scale modeling of tissues using CompuCell3D,” Methods Cell Biol. 110, 325–366 (2012).
129
N. Roehner, E. M. Young, C. A. Voigt, D. B. Gordon, and D. Densmore, “Double dutch: A tool for designing combina-
torial libraries of biological systems,” ACS Synth. Biol. 5, 507–517 (2016).
130
J. Beal, T. Lu, and R. Weiss, “Automatic compilation from high-level biologically-oriented programming language to
genetic regulatory networks,” PLoS One 6, e22490 (2011).
131
M. Pedersen and A. Phillips, “Towards programming languages for genetic engineering of living cells,” J. R. Soc.
Interface 6(Suppl 4), S437–S450 (2009).
132
A. A. Nielsen et al., “Genetic circuit design automation,” Science 352, aac7341 (2016).
133
K. Chung et al., “Structural and molecular interrogation of intact biological systems,” Nature 497, 332–337 (2013).
134
A. Erturk et al., “Three-dimensional imaging of solvent-cleared organs using 3DISCO,” Nat. Protoc. 7, 1983–1995
(2012).
135
R. Kwok, “Five hard truths for synthetic biology,” Nature 463, 288–290 (2010).
136
M. Freutel, H. Schmidt, L. Durselen, A. Ignatius, and F. Galbusera, “Finite element modeling of soft tissues: Material
models, tissue interaction and challenges,” Clin. Biomech. (Bristol, Avon) 29, 363–372 (2014).
137
T. Hirashima, E. G. Rens, and R. M. H. Merks, “Cellular Potts modeling of complex multicellular behaviors in tissue
morphogenesis,” Dev., Growth Differ. 5, 329–339 (2017).
138
R. M. Vroomans, P. Hogeweg, and K. H. ten Tusscher, “Segment-specific adhesion as a driver of convergent extension,”
11 October 2024 11:03:32

PLoS Comput. Biol. 11, e1004092 (2015).
139
A. Shirinifard et al., “3D multi-cell simulation of tumor growth and angiogenesis,” PLoS One 4, e7190 (2009).
140
Y. Setty, “Multi-scale computational modeling of developmental biology,” Bioinformatics 28, 2022–2028 (2012).
141
A. G. Fletcher, M. Osterfield, R. E. Baker, and S. Y. Shvartsman, “Vertex models of epithelial morphogenesis,”
Biophys. J. 106, 2291–2304 (2014).
142
J. Delile, M. Herrmann, N. Peyrieras, and R. Doursat, “A cell-based computational model of early embryogenesis cou-
pling mechanical behaviour and gene regulation,” Nat. Commun. 8, 13929 (2017).
143
M. Marin-Riera, M. Brun-Usan, R. Zimm, T. Valikangas, and I. Salazar-Ciudad, “Computational modeling of develop-
ment by epithelia, mesenchyme and their interactions: A unified model,” Bioinformatics 32, 219–225 (2016).
144
M. Isalan, C. Lemerle, and L. Serrano, “Engineering gene networks to emulate Drosophila embryonic pattern for-
mation,” PLoS Biol. 3, e64 (2005).
145
M. Matsuda, M. Koga, K. Woltjen, E. Nishida, and M. Ebisuya, “Synthetic lateral inhibition governs cell-type bifurca-
tion with robust ratios,” Nat. Commun. 6, 6195 (2015).
146
C. M. Nelson, “On buckling morphogenesis,” J. Biomech. Eng. 138, 021005 (2016).
147
N. L. Nerurkar, L. Mahadevan, and C. J. Tabin, “BMP signaling controls buckling forces to modulate looping morpho-
genesis of the gut,” Proc. Natl. Acad. Sci. U. S. A. 114, 2277–2282 (2017).
148
J. Laurent et al., “Convergence of microengineering and cellular self-organization towards functional tissue man-
ufacturing,” Nat. Biomed. Eng. 1, 939 (2017).
149
Y. Du, E. Lo, S. Ali, and A. Khademhosseini, “Directed assembly of cell-laden microgels for fabrication of 3D tissue
constructs,” Proc. Natl. Acad. Sci. U. S. A. 105, 9522–9527 (2008).
150
Y. Morimoto, A. Y. Hsiao, and S. Takeuchi, “Point-, line-, and plane-shaped cellular constructs for 3D tissue assembly,”
Adv. Drug Delivery Rev. 95, 29–39 (2015).
151
H. Onoe et al., “Metre-long cell-laden microfibres exhibit tissue morphologies and functions,” Nat. Mater. 12, 584–590
(2013).
152
H. Gudapati, M. Dey, and I. Ozbolat, “A comprehensive review on droplet-based bioprinting: Past, present and future,”
Biomaterials 102, 20–42 (2016).
153
S. Wei and X. Tao, “Special issue on 3D cell printing,” Biofabrication 7, 043001 (2015).
154
W. Wang, S. Jin, and K. Ye, “Development of islet organoids from H9 human embryonic stem cells in biomimetic 3D
scaffolds,” Stem Cells Dev. 26, 394–404 (2017).
155
M. Volkner et al., “Retinal organoids from pluripotent stem cells efficiently recapitulate retinogenesis,” Stem Cell Rep.
6, 525–538 (2016).
156
K. Osafune et al., “Marked differences in differentiation propensity among human embryonic stem cell lines,” Nat.
Biotechnol. 26, 313–315 (2008).
157
J. M. Ramirez et al., “Brief report: Benchmarking human pluripotent stem cell markers during differentiation into the
three germ layers unveils a striking heterogeneity: All markers are not equal,” Stem Cells 29, 1469–1474 (2011).

Perspective: The Promise of Multi-Cellular Engineered Living Systems

Uploaded by

Copyright:

Available Formats

Perspective: The Promise of Multi-Cellular Engineered Living Systems

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Perspective: The Promise of Multi-Cellular Engineered Living Systems

Uploaded by

Copyright:

Available Formats

PERSPECTIVE | OCTOBER 11 2018

Perspective: The promise of multi-cellular engineered living

APL Bioeng. 2, 040901 (2018)

Articles You May Be Interested In

Revolutionizing biomedical research: The imperative need for heart–kidney-connected organoids

11 October 2024 11:03:32

Perspective: The promise of multi-cellular engineered living

Recent technological breakthroughs in our ability to derive and differentiate

11 October 2024 11:03:32

except where otherwise noted, is licensed under a Creative Commons Attribution

2473-2877/2018/2(4)/040901/21 2, 040901-1 C Author(s) 2018.

clusters of individually differentiated cells or co-differentiated within a single aggregate of plu-

11 October 2024 11:03:32

Discipline or sub-discipline Contributions to M-CELS

Developmental biology Understanding emergence, morphogenesis, and repair of complex morphologies

11 October 2024 11:03:32

II. DEVELOPMENTAL PROCESSES AND REGENERATION

11 October 2024 11:03:32

11 October 2024 11:03:32

III. CONTROLLING EMERGENCE

11 October 2024 11:03:32

11 October 2024 11:03:32

accelerating as it incorporates recent advances in stem cell biology. Numerous publications

11 October 2024 11:03:32

11 October 2024 11:03:32

Tissue or organ system on-chip Description References

Lung alveolus Alveolus with endothelial and epithelial monolayers. Huh94

11 October 2024 11:03:32

VI. BIOLOGICAL ROBOTICS

11 October 2024 11:03:32

VII. DESIGN PRINCIPLES

VIII. ENABLING TECHNOLOGIES AND COMPUTATIONAL METHODS

11 October 2024 11:03:32

11 October 2024 11:03:32

Technology Application to M-CELS

11 October 2024 11:03:32

11 October 2024 11:03:32

in use—will be of paramount importance to M-CELS biomanufacturing (Fig. 3).154 Improved

11 October 2024 11:03:32

XI. CONCLUSIONS AND OUTLOOK

11 October 2024 11:03:32

11 October 2024 11:03:32

11 October 2024 11:03:32

11 October 2024 11:03:32

11 October 2024 11:03:32

You might also like